Barclays
VRDN icon

Barclays’s Viridian Therapeutics VRDN Stock Holding History

Barclays’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.97M Sell
100,598
-143,675
-59% -$4.27M ﹤0.01% 2362
2025
Q4 		$7.6M Buy
244,273
+36,027
+17% +$988K ﹤0.01% 1893
2025
Q3 		$4.49M Sell
208,246
-22,858
-10% -$412K ﹤0.01% 2292
2025
Q2 		$3.23M Buy
231,104
+107,041
+86% +$1.45M ﹤0.01% 2478
2025
Q1 		$1.67M Sell
124,063
-33,797
-21% -$576K ﹤0.01% 2763
2024
Q4 		$3.03M Buy
157,860
+32,463
+26% +$706K ﹤0.01% 2581
2024
Q3 		$2.85M Buy
125,397
+66,550
+113% +$1.09M ﹤0.01% 2561
2024
Q2 		$766K Sell
58,847
-65,301
-53% -$904K ﹤0.01% 2763
2024
Q1 		$2.17M Sell
124,148
-95,445
-43% -$1.85M ﹤0.01% 2487
2023
Q4 		$4.78M Buy
219,593
+88,036
+67% +$1.39M ﹤0.01% 2133
2023
Q3 		$2.02M Sell
131,557
-125,979
-49% -$2.4M ﹤0.01% 1895
2023
Q2 		$6.13M Buy
257,536
+141,393
+122% +$3.63M ﹤0.01% 1236
2023
Q1 		$2.95M Buy
116,143
+16,823
+17% +$539K ﹤0.01% 1913
2022
Q4 		$2.9M Sell
99,320
-554,431
-85% -$12.8M ﹤0.01% 1997
2022
Q3 		$13.4M Buy
653,751
+635,456
+3,473% +$11.4M 0.01% 750
2022
Q2 		$212K Buy
18,295
+1,295
+8% +$17.4K ﹤0.01% 3387
2022
Q1 		$314K Buy
+17,000
New +$327K ﹤0.01% 3184
2019
Q3 		– Sell
-30
Closed -$1K – 7162
2019
Q2 		$1K Sell
30
-460
-94% -$18.5K ﹤0.01% 6862
2019
Q1 		$20K Buy
490
+489
+48,900% +$22.1K ﹤0.01% 6364
2018
Q4 		$0 Sell
1
-689
-100% -$39.8K ﹤0.01% 7373
2018
Q3 		$57K Buy
690
+565
+452% +$53.3K ﹤0.01% 6004
2018
Q2 		$12K Sell
125
-261
-68% -$27.6K ﹤0.01% 6474
2018
Q1 		$41K Buy
386
+216
+127% +$23.5K ﹤0.01% 6037
2017
Q4 		$27K Buy
170
+151
+795% +$19.2K ﹤0.01% 6141
2017
Q3 		$3K Sell
19
-244
-93% -$41K ﹤0.01% 6611
2017
Q2 		$51K Buy
263
+128
+95% +$21.6K ﹤0.01% 5355
2017
Q1 		$25K Buy
+135
New +$23.3K ﹤0.01% 5709
2015
Q3 		– Sell
-280
Closed -$126K – 7077
2015
Q2 		$126K Buy
+280
New +$113K ﹤0.01% 4497

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Barclays's VRDN Position: Q1 2026 in Review

Barclays reduced its Viridian Therapeutics (VRDN) stake by 59% in Q1 2026, selling an estimated $4.27M and leaving 100,598 shares worth $1.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2362.

Barclays first reported a position in VRDN in Q2 2015 and has held it in 28 quarters since. The position peaked at $13.4M in Q3 2022. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Barclays held 100,598 shares of Viridian Therapeutics worth $1.97M as of Q1 2026.
  • Barclays sold 143,675 Viridian Therapeutics shares in Q1 2026, an estimated $4.27M.
  • Viridian Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2362 holding.
  • Barclays first reported a position in Viridian Therapeutics in Q2 2015 and has held it in 28 quarters since.
  • Barclays's Viridian Therapeutics position peaked at $13.4M in Q3 2022.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.